Dublin, Feb. 02, 2017 -- Research and Markets has announced the addition of the "Wirelessly Enabled Injection Devices to 2022" report to their offering.
For self-administration, adherence with drug therapy and disease management protocols has become a primary concern within the healthcare and pharmaceutical industries. For chronic conditions adherence has a direct effect on the patient's quality-of-life.
Wirelessly enabled devices - drug injection devices that are designed to address the patient adherence issue by reminding and recording data about patient dosing activity and making it available to HCPs - are gaining interest among industry and managed care participants. Efforts to enhance adherence have a non-negligible effect on drug formulations and delivery decisions, and are a significant factor in the prescribing decisions of most physicians. The connected device ecosystem includes OEM device suppliers, drug developers, human factors consultants and aftermarket third-party devices.
Wirelessly Enabled Injection Devices - What You Will Learn
- What drug injection devices incorporate wireless connectivity technology, how do they work and what new capabilities do they offer to patients and their HCPs?
- What benefits do wirelessly enabled drug injectors provide to patients in the area of improved adherence? Patient reported outcomes? HCP/patient communication?
- What therapeutic areas are the current focus of wirelessly enabled devices?
- Who are the companies behind the growth of wirelessly enabled injection devices? What are their development activities and corporate alliances and affiliations
- What is the importance of pharma-device alliances and design partnerships on wirelessly enabled drug injection device commercialization and market access?
- What does the current market for wirelessly enabled drug injection devices look like? What will it look like in 2022?
- What are the key market drivers for the growth of wirelessly enabled injection devices?
Key Topics Covered:
1. Executive Summary
2. Wireless Injection Devices - The Opportunity
3. Injectable Device Technology
- Market Drivers
- The Growth of Self-Administration
- The Rise in Home Healthcare
- The Cost of Non-Adherence
- Biological Injectables and Patient Safety
- The Impact of Developing Economies
4. Connectivity Technologies
- Wireless Technologies
- Bluetooth
- Cellular
- Near Field Communications
- RFID
5. Wirelessly Enabled Device Classes
- Wearable Devices
- Handheld Devices
- Device Segments
- Non-drug Specific Connected Injectors
- Automated Connected Injectors
- Vendor-specific Connectivity Platforms
- Third Party Connectivity Devices
6. Near-term Markets for Connected Injection Devices
- Anaphylaxis
- Autoimmune Disease
- Cardiovascular
- Diabetes
- Hormone Replacement
7. Market Factors
- Regulatory Issues
- HIPAA and Patient Privacy
- Data Security
- Cybersecurity and Patient Safety
- Patient Safety
- User Training
8. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/3zjs5t/wirelessly
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infusions and Injectables , Needles and Syringes


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



